Zymfentra (infliximab-dyyb)

Manufacturer:
Celltrion
Route of Administration: 
Subcutaneous
Site of Care:
Outpatient
Website: 
  • Manufacturer Website

Approved Indication:

  • maintenance treatment of moderaly to severely active ulcerative colitis in adults following treatment with an infliximab product administered intravenously
  • maintenance treatment of moderately-to-severely active Crohn’s disease in adults following treatment with an infliximab product administered intravenously>

Conditions:

  • Crohn’s Disease
  • Ulcerative Colitis

Therapeutic Area:

  • Gastroenterology